Matthew Pauls
2020 - Mast Therapeutics
In 2020, Matthew Pauls earned a total compensation of $1.9M as Chief Executive Officer at Mast Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $74,648 |
|---|---|
| Option Awards | $1,352,163 |
| Salary | $169,697 |
| Stock Awards | $299,999 |
| Other | $39,796 |
| Total | $1,936,303 |
Pauls received $1.4M in option awards, accounting for 70% of the total pay in 2020.
Pauls also received $74.6K in non-equity incentive plan, $169.7K in salary, $300K in stock awards and $39.8K in other compensation.
Rankings
In 2020, Matthew Pauls' compensation ranked 5,661st out of 13,090 executives tracked by ExecPay. In other words, Pauls earned more than 56.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,661 out of 13,090 | 57th |
Division Manufacturing | 2,338 out of 5,620 | 58th |
Major group Chemicals And Allied Products | 934 out of 2,253 | 59th |
Industry group Drugs | 808 out of 1,953 | 59th |
Industry Pharmaceutical Preparations | 602 out of 1,458 | 59th |
Source: SEC filing on April 19, 2022.
Pauls' colleagues
We found two more compensation records of executives who worked with Matthew Pauls at Mast Therapeutics in 2020.